Strategies to minimize immunological and nonimmunological risk factors in the renal transplant population

Transplantation

Volumn 72, Issue 6 SUPPL., 2001, Pages

  First, M R ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN; AZATHIOPRINE; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN; GLUCOSE; IMMUNOSUPPRESSIVE AGENT; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DISEASE SEVERITY; GRAFT FAILURE; GRAFT REJECTION; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; POPULATION RISK; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0035960069     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200109271-00007     Document Type: Conference Paper

References (37)

1. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
2. Tacrolimus (FK 506) in kidney transplantation: Three-year survival results of the U.S. multicenter, randomized, comparative trial
3. Tacrolimus versus cyclosporine in kidney transplantation: Five-year survival results of the U.S. multicenter, randomized, comparative study
4. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group
5. Four-year follow-up of the European tacrolimus multicenter renal study
6. Immunological and nonimmunologieal risk factors with tacrolimus and Neoral in renal transplant recipients: An interim report
7. A prospective, randomized, multicentre study to compare the efficacy and safety of tacrolimus and ciclosporin-microemulsion in renal transplantation
8. Analysis of primary and recurrent acute rejections after renal transplantation in a large European multicentre trial involving tacrolimus and cyclosporin-microemulsion
9. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival
10. Immunologically high-risk recipient strategies
11. Immunosuppressive regimens and their effect on renal allograft outcome
12. Analyses of the UNOS Scientific Renal Transplant Registry at three years: Early events affecting transplant success
13. Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys
14. Racial disparities in renal transplant outcomes
15. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression
16. Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR)
17. Cardiovascular disease after renal transplantation
18. Corticosteroid withdrawal after renal transplantation in the cyclosporine era: Timing, benefits and risks
19. Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: The Chicago experience
20. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients
21. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients
22. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: A randomized study
23. Kidney transplantation without prednisone
24. Early corticosteroid cessation at one week following kidney transplant under tacrolimus and mycophenolate mofetil (MMF) immunosuppression, three-year follow-up
25. Withdrawal of steroids after renal transplantation: Clinical predictors of outcome
26. Cardiovascular disease in kidney transplant patients
27. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: A Southeastern Organ Procurement Foundation Multicenter Clinical Study
28. Sirolimus (rapamycin)-based therapy in human renal transplantation
29. Effects of cyclosporine therapy on plasma lipoprotein levels
30. Lipoprotein patterns in renal transplant patients: A comparison between FK 506 and cyclosporine A patients
31. Conversion to tacrolimus in hyperlipidemic patients
32. Risk for posttransplant diabetes mellitus with current immunosuppressive medications
33. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients
34. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients
35. Two year follow-up of a randomized multicenter kidney transplant study comparing tacrolimus (PG)+azathioprine (AZA) vs. cyclosporine (Neoral)+mycophenolate mofetil (MMF) vs tacrolimus+MMF
36. Calcineurin-inhibitors in renal transplantation: Too precious to be abandoned